Which bonds? An analysis of CommBank Retail Bonds
The terms of this offer are refreshingly simple. It’s not the greatest opportunity you’ll ever see but it does offer something of a safe haven.
Westfield demerger: Key dates and stag profit potential
The key dates leading up to the Westfield demerger require securityholders, and those hoping for a stag profit, to make some decisions. Nathan Bell explains.
Harvey Norman back in bargain bin
It’s a fantastic time to buy a flat panel TV but not to sell them, as Harvey Norman is discovering. So why are we upgrading the stock to Long Term Buy?
Seven TELYS4 on hold
There’s a lot to dislike about the Seven Group TELYS4 preference shares but an attractive running yield is sufficient compensation.
Brambles pulls out the plastic for IFCO
A large bolt-on acquisition gives Brambles more clout in one of the faster-growing segments of its business.
Iron ore: It's (not) different this time
There’s a popular assumption that iron ore prices will stay high. But, as Gaurav Sodhi explains, the best solution to high prices is…high prices.
Woodside Petroleum: Shell sells
Shell's exit from the Woodside share register has raised questions, but it might also raise an opportunity.
The Ideas Lab: RHG still offers a 20% return
Despite the massive increase in its share price today, if you are on a low tax rate or have capital gains which can be utilised RHG is still great value.
Time to rejoice at RHG
It’s been a long and winding road but, finally, our original investment hypothesis has played out profitably for all.
The radio sector: Static
Video may have killed the radio star, but it'll be the internet that kills the radio industry.
Westfield locks and loads with capital raising
After battening down the hatches during the credit crisis, Westfield is reloading for growth. Nathan Bell explains the battle plan.
Easy profits for Tabcorp shareholders
Tabcorp's latest capital raising creates an opportunity to pocket some cash for shareholders who do not wish to invest more money.
Sirtex enters remission
There’s a lot to dislike about Sirtex Medical. But its revolutionary liver cancer treatment works, the market for it is huge and the company is profitable and pays a dividend.
Why you should steer clear of NAB and ANZ
The big banks enjoyed a strong reporting season. But the strategies of National Australia Bank and ANZ make them our least preferred options in the sector.
Call 1300 880 160
Start a chat
Schedule a call
